1538 related articles for article (PubMed ID: 18522288)
21. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
Kastelan D; Giljevic Z; Kraljevic I; Korsic M
Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
[TBL] [Abstract][Full Text] [Related]
22. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Goeree R; Blackhouse G; Adachi J
Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
[TBL] [Abstract][Full Text] [Related]
25. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
26. Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.
Nielsen DS; Langdahl BL; Sørensen OH; Sørensen HA; Brixen KT
Scand J Public Health; 2010 Jul; 38(5):502-7. PubMed ID: 20484306
[TBL] [Abstract][Full Text] [Related]
27. [Who are the candidates for the treatment by raloxifen ?].
Hagino H
Clin Calcium; 2004 Oct; 14(10):111-3. PubMed ID: 15577141
[TBL] [Abstract][Full Text] [Related]
28. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
29. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
30. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Gentilella R; Agnusdei D; Iori N; Nuti R;
J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811
[TBL] [Abstract][Full Text] [Related]
31. Compliance with osteoporosis treatment guidelines in postmenopausal women.
Mountjoy CR; Shrader SP; Ragucci KR
Ann Pharmacother; 2009 Feb; 43(2):242-50. PubMed ID: 19196838
[TBL] [Abstract][Full Text] [Related]
32. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
33. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.
Salaffi F; Cimmino MA; Malavolta N; Carotti M; Di Matteo L; Scendoni P; Grassi W;
J Rheumatol; 2007 Jul; 34(7):1551-60. PubMed ID: 17516618
[TBL] [Abstract][Full Text] [Related]
34. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
[TBL] [Abstract][Full Text] [Related]
35. [Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis].
Hosoi T
Clin Calcium; 2007 Sep; 17(9):1419-23. PubMed ID: 17767033
[TBL] [Abstract][Full Text] [Related]
36. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
[TBL] [Abstract][Full Text] [Related]
37. The long-term effect of raloxifene on the genitourinary tract.
Sharma S; Albertazzi P; Bottazzi M
Climacteric; 2007 Jun; 10(3):244-8. PubMed ID: 17487651
[TBL] [Abstract][Full Text] [Related]
38. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
39. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported impact of urinary incontinence--results from treatment seeking women in 14 European countries.
Monz B; Pons ME; Hampel C; Hunskaar S; Quail D; Samsioe G; Sykes D; Wagg A; Papanicolaou S
Maturitas; 2005 Nov; 52 Suppl 2():S24-34. PubMed ID: 16297579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
